Claude Haiku 5.5 is 90% cheaper per token, but the bill depends on four other numbers

Claude Haiku 5.5 costs 90% less per token up to 100,000 tokens. Here is the real bill after the tokeniser change, the effort default and the switch traps.
Coinbase Advanced meets a returning Pro: one trust brand, two doors, and the promotion rules between them

Coinbase Advanced gets a sibling as Pro returns and Deribit joins Coinbase Global Exchange. Here are five smart checks for brand tiers and promotion rules.
Post quantum cryptography meets the medical device: a headline that overreads its data

Post quantum cryptography in healthcare: Forescout’s 6% IoMT figure measures SSH, not upgrade limits. Here is the honest read and the claims that stay true.
Meta AI ads can now run the account. The guardrails are still yours to write

Meta AI ads now include video generation, agent testing and an expanding Ads MCP server. Here are five practical guardrails before an agent touches your budget.
OpenAI API rate limits drop to three tiers, and a cheaper way to decide arrives

OpenAI cut its API tiers from five to three and put the Decisions API in beta. Here are the OpenAI API rate limits, the real costs and the tests to run first.
McDonald’s AI priced the Big Mac. A court will now decide whether that was coordination

McDonald’s AI pricing lawsuit puts dynamic pricing on trial: what the Fresno Big Mac gap shows, what the chain denies, and the rule for your own tools.
Spotify pay per stream: why an $8M fraud exposes the pro-rata illusion

An $8M streaming fraud case reaches sentencing. What Spotify pay per stream really means, why pro-rata maths dilutes royalties, and 5 vendor checks for Monday.
AI medical devices: the claim a regulator can quote back at you

AI medical devices face two new regulatory reads: the FDA’s discussion paper, comments due 19 October, and 44 UK recommendations. Six steps for AI claims.
A brand positioning statement is short. Thorne’s took diaries, a survey and a year

A brand positioning statement is short, but Thorne’s took diaries, a survey and interviews. What its reported $3.8bn P&G deal teaches about writing one.
An FDA untitled letter, a word change and the quiet lesson for GLP-1 advertising

An FDA untitled letter hit Novo’s Wegovy ad, and Novo now says customers, not patients. Five practical rules for telehealth and GLP-1 advertising teams.

